2025
SJR Q1
JCR Q2 · 1,8
OA
11 eşleşen makale
SCIE
Dergi ayrıntısı
Journal of Endovascular Therapy
- Yayıncı
- SAGE Publications Inc.
- Ülke
- United States · Northern America
- Tür
- journal
- ISSN
-
1526602815451550
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 0,757
- Quartile Q1
- H-Index 113
- Atıf/yayın 1,92
- Doküman (3y) 442
- Atıf (3y) 942
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 1,8
- 5Y JIF 2,1
- JCI 0,55
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Cardiology and Cardiovascular Medicine Q2
- Medicine (miscellaneous) Q2
- Radiology, Nuclear Medicine and Imaging Q2
- Surgery Q1
Alanlar
- Medicine
WoS kategorileri
- Surgery | Peripheral Vascular Diseases
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q2 | 0,757 | 1,8 | 2,1 | 0,55 | Q3 | 113 |
| 2024 | Q1 | Q3 | 1,003 | 1,5 | 2,2 | 0,57 | Q3 | 112 |
| 2023 | Q1 | Q2 | 1,006 | 1,7 | 2,5 | 0,68 | Q2 | 112 |
| 2022 | Q1 | Q2 | 1,114 | 2,6 | 2,8 | 0,75 | Q2 | 112 |
| 2021 | Q1 | Q2 | 1,201 | 3,1 | 3,3 | 0,93 | Q1 | 112 |
| 2020 | Q1 | Q2 | 1,72 | 3,5 | 3,4 | 1,04 | Q1 | 112 |
| 2019 | Q1 | Q1 | 1,776 | 3,1 | 2,9 | 1,17 | Q1 | 112 |
| 2018 | — | Q1 | — | 3 | 2,9 | 1,05 | Q1 | — |
| 2017 | Q1 | Q2 | 1,791 | 2,7 | 3 | 1,08 | Q1 | 112 |
| 2016 | Q1 | Q1 | 1,667 | 2,8 | 2,9 | — | — | 112 |
| 2015 | Q1 | Q1 | 1,931 | 3,1 | 2,9 | — | — | 112 |
| 2014 | Q1 | Q1 | 1,948 | 3,4 | 2,9 | — | — | 112 |
| 2013 | Q1 | Q1 | 2,074 | 3,6 | 3,1 | — | — | 112 |
| 2012 | Q1 | Q1 | 1,692 | 2,7 | 2,8 | — | — | 112 |
| 2011 | Q1 | Q1 | 1,762 | 2,9 | 2,9 | — | — | 112 |
| 2010 | Q1 | Q1 | 1,652 | 2,9 | 2,9 | — | — | 112 |
| 2009 | — | Q1 | — | 2,9 | 2,9 | — | — | — |
| 2008 | — | Q1 | — | 2,7 | 2,5 | — | — | — |
| 2007 | — | Q1 | — | 2,4 | 2,3 | — | — | — |
| 2006 | — | Q1 | — | 2,1 | — | — | — | — |
| 2005 | — | Q2 | — | 1,8 | — | — | — | — |
| 2004 | — | Q1 | — | 1,8 | — | — | — | — |
| 2003 | — | Q1 | — | 2,6 | — | — | — | — |
| 2002 | — | Q1 | — | 2,6 | — | — | — | — |
| 2001 | — | Q1 | — | 2,1 | — | — | — | — |
| 2000 | — | — | — | — | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 66/100 |
| 2025 | SURGERY | SCIE | Q2 | Q3 | 157/321 |
| 2024 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 73/98 |
| 2024 | SURGERY | SCIE | Q3 | Q3 | 175/314 |
| 2023 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 64/96 |
| 2023 | SURGERY | SCIE | Q2 | Q2 | 135/292 |
| 2022 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 43/68 |
| 2022 | SURGERY | SCIE | Q2 | Q2 | 75/213 |
| 2021 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q1 | 40/67 |
| 2021 | SURGERY | SCIE | Q2 | Q2 | 74/213 |
| 2020 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q1 | 28/65 |
| 2020 | SURGERY | SCIE | Q2 | Q1 | 58/211 |
| 2019 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q1 | 22/65 |
| 2019 | SURGERY | SCIE | Q1 | Q1 | 46/210 |
| 2018 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q1 | 25/65 |
| 2018 | SURGERY | SCIE | Q1 | Q1 | 50/203 |
| 2017 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q1 | 32/65 |
| 2017 | SURGERY | SCIE | Q2 | Q1 | 52/200 |
| 2016 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 32/63 |
| 2016 | SURGERY | SCIE | Q1 | — | 49/197 |
| 2015 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 21/63 |
| 2015 | SURGERY | SCIE | Q1 | — | 28/200 |
| 2014 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 19/60 |
| 2014 | SURGERY | SCIE | Q1 | — | 24/198 |
| 2013 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 19/65 |
| 2013 | SURGERY | SCIE | Q1 | — | 17/204 |
| 2012 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 31/68 |
| 2012 | SURGERY | SCIE | Q1 | — | 31/199 |
| 2011 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 20/68 |
| 2011 | SURGERY | SCIE | Q1 | — | 29/199 |
| 2010 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 21/68 |
| 2010 | SURGERY | SCIE | Q1 | — | 27/188 |
| 2009 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 22/61 |
| 2009 | SURGERY | SCIE | Q1 | — | 22/167 |
| 2008 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 24/56 |
| 2008 | SURGERY | SCIE | Q1 | — | 24/148 |
| 2007 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 24/54 |
| 2007 | SURGERY | SCIE | Q1 | — | 25/139 |
| 2006 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 27/52 |
| 2006 | SURGERY | SCIE | Q1 | — | 31/137 |
| 2005 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 30/51 |
| 2005 | SURGERY | SCIE | Q2 | — | 35/139 |
| 2004 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 25/51 |
| 2004 | SURGERY | SCIE | Q1 | — | 34/139 |
| 2003 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 16/52 |
| 2003 | SURGERY | SCIE | Q1 | — | 13/141 |
| 2002 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 15/52 |
| 2002 | SURGERY | SCIE | Q1 | — | 14/141 |
| 2001 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 20/50 |
| 2001 | SURGERY | SCIE | Q1 | — | 26/139 |
| 2000 | PERIPHERAL VASCULAR DISEASE | SCIE | — | — | — |
| 2000 | SURGERY | SCIE | — | — | — |